- Home
- PHGE vs BTBD Comparison
PHGE vs BTBD Comparison
Compare PHGE & BTBD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHGE
- BTBD
- Stock Information
- Founded
- PHGE 2015
- BTBD 1987
- Country
- PHGE Israel
- BTBD United States
- Employees
- PHGE N/A
- BTBD N/A
- Industry
- PHGE Biotechnology: Pharmaceutical Preparations
- BTBD Restaurants
- Sector
- PHGE Health Care
- BTBD Consumer Discretionary
- Exchange
- PHGE Nasdaq
- BTBD Nasdaq
- Market Cap
- PHGE 12.6M
- BTBD 13.0M
- IPO Year
- PHGE N/A
- BTBD 2021
- Fundamental
- Price
- PHGE $0.55
- BTBD $1.84
- Analyst Decision
- PHGE Strong Buy
- BTBD
- Analyst Count
- PHGE 1
- BTBD 0
- Target Price
- PHGE $15.00
- BTBD N/A
- AVG Volume (30 Days)
- PHGE 292.1K
- BTBD 930.8K
- Earning Date
- PHGE 11-13-2025
- BTBD 11-12-2025
- Dividend Yield
- PHGE N/A
- BTBD N/A
- EPS Growth
- PHGE N/A
- BTBD N/A
- EPS
- PHGE N/A
- BTBD N/A
- Revenue
- PHGE N/A
- BTBD $14,533,449.00
- Revenue This Year
- PHGE N/A
- BTBD N/A
- Revenue Next Year
- PHGE N/A
- BTBD N/A
- P/E Ratio
- PHGE N/A
- BTBD N/A
- Revenue Growth
- PHGE N/A
- BTBD 1.58
- 52 Week Low
- PHGE $0.34
- BTBD $1.00
- 52 Week High
- PHGE $1.16
- BTBD $5.60
- Technical
- Relative Strength Index (RSI)
- PHGE 56.74
- BTBD 49.54
- Support Level
- PHGE $0.50
- BTBD $1.80
- Resistance Level
- PHGE $0.54
- BTBD $2.15
- Average True Range (ATR)
- PHGE 0.03
- BTBD 0.13
- MACD
- PHGE 0.00
- BTBD 0.01
- Stochastic Oscillator
- PHGE 71.42
- BTBD 49.21
About PHGE BiomX Inc. COmmon Stock
BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).
About BTBD BT Brands Inc.
BT Brands Inc operates and owns a fast-food restaurant called Burger Time. The company also operates in Minnesota as a franchisee of Dairy Queen. It offers a variety of burgers and other affordably priced foods such as chicken sandwiches, pulled pork sandwiches, chicken chunks, side dishes, and soft drinks.